194 related articles for article (PubMed ID: 27687905)
1. Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism.
Krause M; Henningsen A; Torge A; Juhl D; Junker R; Kenet G; Kowalski D; Limperger V; Mesters R; Anonymous ; Rocke A; Shneyder M; Clausnizer H; Schiesewitz H; Nowak-Göttl U
Thromb Res; 2016 Dec; 148():145-151. PubMed ID: 27687905
[No Abstract] [Full Text] [Related]
2. Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience.
Arachchillage D; Reynolds R; Devey T; Maclean R; Kitchen S; van Veen JJ
Thromb Res; 2016 Nov; 147():32-35. PubMed ID: 27669125
[No Abstract] [Full Text] [Related]
3. Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry.
Bott-Kitslaar DM; Saadiq RA; McBane RD; Loprinzi CL; Ashrani AA; Ransone TR; Wolfgram AA; Berentsen MM; Wysokinski WE
Am J Med; 2016 Jun; 129(6):615-9. PubMed ID: 26797081
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
[TBL] [Abstract][Full Text] [Related]
5. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism.
Sciascia S; Breen K; Hunt BJ
Blood Coagul Fibrinolysis; 2015 Jun; 26(4):476-7. PubMed ID: 25923780
[No Abstract] [Full Text] [Related]
8. Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban.
Tardy-Poncet B; Piot M; Montmartin A; Burdier A; Chalayer E; Tardy B
Thromb Haemost; 2015 Aug; 114(3):652-4. PubMed ID: 26062524
[No Abstract] [Full Text] [Related]
9. Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.
Beyer-Westendorf J; Lensing AW; Arya R; Bounameaux H; Cohen AT; Wells PS; Middeldorp S; Verhamme P; Hughes R; Kucher N; Pap AF; Trajanovic M; Prins MH; Prandoni P; Weitz JI
Thromb Res; 2017 Jan; 149():29-37. PubMed ID: 27886530
[TBL] [Abstract][Full Text] [Related]
10. The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.
Ten Cate H; Lensing AWA; Weitz JI; Middeldorp S; Beyer-Westendorf J; Kubitza D; Brighton T; Raskob GE; Mismetti P; Prandoni P; Gebel M; Prins MH
Thromb Res; 2018 Oct; 170():75-83. PubMed ID: 30121419
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban-induced liver injury: Results from a venous thromboembolism registry.
Lambert A; Cordeanu M; Gaertner S; Nouri S; Alt M; Stephan D
Int J Cardiol; 2015 Jul; 191():265-6. PubMed ID: 25981364
[No Abstract] [Full Text] [Related]
12. [Good efficacy and safety profile in clinical practice].
MMW Fortschr Med; 2015 Nov; 157(20):66-7. PubMed ID: 26977521
[No Abstract] [Full Text] [Related]
13. Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency.
Minami K; Kumagai K; Sugai Y; Nakamura K; Naito S; Oshima S
Intern Med; 2018 Jul; 57(14):2025-2028. PubMed ID: 29526957
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Rivaroxaban for Extremely Aged Patients with Venous Thromboembolism: A Retrospective, Cross-Sectional Real-World Study.
Wang C; Fan X; Nie L; Wang Q; Li S; Zheng W; Zhang W; Dai W; Chen M
Clin Interv Aging; 2024; 19():1103-1116. PubMed ID: 38915432
[TBL] [Abstract][Full Text] [Related]
15. [Rivaroxaban as monotherapy in patients with venous thromboembolism].
Krivoshchekov EP; Migunov IA; Romanov VE
Khirurgiia (Mosk); 2016; (10):61-65. PubMed ID: 27804937
[TBL] [Abstract][Full Text] [Related]
16. Treatment of venous thromboembolism in a 22-year-old woman taking an oral contraceptive pill.
Shafran DM; Wu C
CMAJ; 2017 Nov; 189(47):E1459-E1460. PubMed ID: 29180385
[No Abstract] [Full Text] [Related]
17. Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease.
Theberge I; Bowdridge J; Forgie MA; Carrier M; Louzada M; Siquiera L; Rhodes M; Wells PS
Thromb Res; 2017 Apr; 152():4-6. PubMed ID: 28192715
[No Abstract] [Full Text] [Related]
18. Practical management of rivaroxaban for the treatment of venous thromboembolism.
Imberti D; Benedetti R
Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
[TBL] [Abstract][Full Text] [Related]
20. Effect of rivaroxaban starter packs on emergency department throughput.
Ayers GT; D'Amico PhD F; Farrah RM; Klatt PM; Baumgartner MA
Am J Emerg Med; 2018 Sep; 36(9):1698-1699. PubMed ID: 29429797
[No Abstract] [Full Text] [Related]
[Next] [New Search]
